Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

----- --- ----- --- Total costs and expenses 53,434 28,649 153,652 87,974 ------ ------ ------- ------ Operating (loss) income (3,414) 19,047 78,655 115,796 Interest income 828 7,219 14,296 24,265 Interest expense (1,532) (1,434) (5,852) (4,395) ----- ----- ----- ----- (Loss) income before income tax expense (4,118) 24,832 87,099 135,666 Income tax (benefit) expense (3,141) 4,461 19,482 40,313 ----- ----- ------ ------ Net (loss) income $(977) $20,371 $67,617 $95,353 === ====== ====== ====== Basic net (loss) income per share $(0.01) $0.29 $0.95 $1.37 ==== ==== ==== ==== Diluted net (loss) income per share $(0.01) $0.25 $0.83 $1.21 ==== ==== ==== ==== Shares used in computing net income per share Basic 75,693 69,887 71,391 69,827 ====== ====== ====== ====== Diluted 75,693 83,830 85,712 80,891 ====== ====== ====== ====== Year ended Statement of Cash Flows: December 31, December 31, ----------- ----------- (in thousands) 2008
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... development company specialized in oncology and endocrine therapy, ... ("Keryx") (Nasdaq: KERX), has been granted orphan-drug designation ... for perifosine, Aeterna Zentaris, novel, potentially first-in-class, oral ...
... , , , ... Residents and Students now Able to Prepare, Review and Test,Knowledge of Common Medical Procedures ... Elsevier, the ... physicians,residents and students will be able to visualize and review over 300 top,medical procedures ...
... studies have uncovered a number of DNA variants associated ... variants lie outside of genes, posing a challenge to ... In a report published online today in Genome ... functional DNA element associated with prostate cancer, lending new ...
Cached Biology Technology:Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 3Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 4New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 2New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 3New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 4Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 2Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 3
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... DALLAS Jan. 30, 2014 Patients who have ... and pay closer attention to their nutritional intake, a ... published in the Journal of Investigative Medicine , ... that despite nutritional counseling over a three-month period, most ...
... expect that plants are food sources, but only after an adult ... new research published in Psychological Science , a journal of ... watching an adult put part of a plant and part of ... of age preferentially identify the plant as the food source. ...
... A Kansas State University engineer has made a breakthrough ... of mechanical and nuclear engineering, and his student researchers ... -- made of interleaved molybdenum disulfide and graphene nanosheets ... store sodium atoms and a flexible current collector. The ...
Cached Biology News:Gastric banding patients should closely monitor nutrition following surgery 2Gastric banding patients should closely monitor nutrition following surgery 3Infants know plants provide food, but need to see they're safe to eat 2Engineer brings new twist to sodium-ion battery technology 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: